Skip to content

Effect of Midodrine on Pediatric Syncope

Investigating the effect of oral midodrine in the prevention of syncope attacks in primary school children (6-12 years old)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211012052736N1
Enrollment
100
Registered
2025-08-04
Start date
2025-07-23
Completion date
Unknown
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syncope. Syncope and collapse

Interventions

Intervention 1: Intervention group: Intervention group: Participants in this group will receive oral midodrine along with standardized non-pharmacological management.Drug: Midodrine, an alpha-adrenerg

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Primary school children aged 6 to 12 years with a history of recurrent syncope attacks Normal EEG findings Normal ECG and echocardiography findings (no arrhythmia, cardiomyopathy, or structural heart problems) Positive head-up tilt table test (HUTT) results

Exclusion criteria

Exclusion criteria: Pre-existing cardiac arrhythmias, cardiomyopathy, or structural heart abnormalities identified via ECG or echocardiography Severe comorbidities such as uncontrolled hypertension, chronic kidney disease, or severe asthma Concurrent use of medications affecting syncope or blood pressure (e.g., beta-blockers, fludrocortisone, diuretics) Known hypersensitivity or allergy to midodrine Inability to comply with the study protocol, including monthly follow-ups or adherence to non-pharmacological measures Presence of neurological disorders or conditions affecting consciousness

Design outcomes

Primary

MeasureTime frame
Frequency of syncope attacks over the six-month follow-up period. Timepoint: Baseline (pre-intervention); one month, three months, and six months post-treatment. Method of measurement: Monitored through parental reports and verified during monthly clinic visits.

Secondary

MeasureTime frame
Incidence of any drug-related adverse effects, including supine hypertension, palpitations, headache, piloerection, and urinary retention. Timepoint: Weekly (via parental reports) and monthly during clinic visits, over a six-month period. Method of measurement: Assessed through a standardized questionnaire and parental reports.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Zare-Zardini

Yazd University of Medical Sciences

hadizarezardini@gmail.com+98 35 3822 9104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026